Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
From outside firms

Analysis and Perspectives

Commentary and analysis from outside consulting and policy firms. Not part of Medicaid Monitor's independently scored news coverage. Each piece links back to the firm's original publication.

Avalere · Jul 9

USPSTF Recommendations Drive Preventive Care Coverage Requirements for Medicaid and Commercial Plans

USPSTF's A and B grade recommendations mandate coverage without cost sharing under the ACA for both commercial and public insurers, including Medicaid programs. The piece outlines how diagnostics developers and biopharmaceutical companies can strategically engage with USPSTF through new topic nominations or existing topic reconsiderations to influence preventive care coverage policies. While focused primarily on the evidence generation and USPSTF engagement process, the coverage mandate implications extend directly to Medicaid managed care organizations' benefit design and compliance obligations.

Read at advisory.avalerehealth.com →
Avalere · Jul 8

Medicaid Unwinding and New Federal Redetermination Rules Threaten Adult Vaccine Access

Avalere examines how the end of Medicaid continuous enrollment led to 10 million disenrollments in 12 months, creating vaccine access barriers despite IRA protections, with state-by-state variation complicating national assessment. The analysis warns that new federal requirements under the One Big Beautiful Bill Act—including six-month eligibility redeterminations and work requirements—will likely worsen coverage churn and vaccination gaps. MCOs and state programs face intensifying challenges in maintaining preventive care continuity as enrollment volatility increases under the new policy environment.

advisory.avalerehealth.com →
Avalere · Jul 7

Federal Diabetes Research Program Yields $50B in Savings, Including Through Medicaid

Avalere estimates that research funded by the Special Diabetes Program has generated over $50 billion in federal healthcare savings through technologies like continuous glucose monitors and automated insulin delivery systems used by Medicare, Medicaid, and VA beneficiaries. The analysis focuses on direct medical cost reductions from improved diabetes management and reduced complications, with Medicaid representing one of three major public payers benefiting from these innovations. The findings have implications for how states and MCOs assess value from diabetes management technologies and clinical interventions.

advisory.avalerehealth.com →
Avalere · Jul 2

CMS Releases 400+ New Diagnosis Codes for FY 2026, Effective October 1

The Centers for Medicare & Medicaid Services and CDC have announced over 400 new ICD-10-CM diagnostic codes taking effect October 1, 2025, including codes for diabetes remission, multiple sclerosis progression, and various other conditions. These coding changes will affect claims processing, documentation requirements, and reimbursement methodologies for Medicaid managed care plans that rely on encounter data and risk adjustment. MCOs will need to update systems, train providers, and adjust coding workflows ahead of the October implementation date.

advisory.avalerehealth.com →
Avalere · Jun 30

ACIP Reconstitution May Reshape Vaccine Coverage Requirements for Medicaid Plans

The Advisory Committee on Immunization Practices was reconstituted with new members appointed by HHS Secretary Kennedy, signaling potential shifts in vaccine policy that could affect coverage mandates. Since ACIP recommendations trigger first-dollar coverage requirements across insurance programs including Medicaid, changes in the committee's direction could impact formulary requirements, preventive care mandates, and cost structures for Medicaid managed care plans. The piece examines how the committee's new composition may influence immunization schedules that directly affect MCO coverage obligations.

advisory.avalerehealth.com →
Avalere · Jun 26

Proposed AHRQ Budget Cuts Could Disrupt Medicaid Preventive Care Coverage Requirements

The Trump administration's proposed elimination of AHRQ's independent structure and $129 million budget cut threatens the USPSTF's ability to produce evidence-based preventive care recommendations. Because Medicaid managed care plans are required to cover USPSTF Grade A and B services without cost-sharing under the ACA, disruption to this process could create coverage uncertainty and compliance challenges for MCOs. The reorganization raises concerns about the independence and capacity of the evidence review process that drives mandatory preventive benefit design across commercial and public insurance.

advisory.avalerehealth.com →
Avalere · Jun 12

Trump Administration Pivots Behavioral Health Policy Away from Integration Toward Cost Control

The administration is shifting away from behavioral health integration and parity enforcement through changes at CMMI, potential weakening of mental health parity requirements, and proposed cuts to SAMHSA and CDC. These policy changes could significantly affect how Medicaid managed care plans structure behavioral health benefits, enforce parity, and participate in value-based models. The proposed FY 2026 budget cuts to SAMHSA ($1.1B reduction) and consideration of dissolving the agency altogether would directly impact state Medicaid behavioral health infrastructure and MCO programming.

advisory.avalerehealth.com →
Avalere · Jun 10

Medicare Drug Price Negotiation Changes Could Affect Medicaid Best Price Calculations

CMS released draft guidance for the 2028 cycle of Medicare drug price negotiations under the Inflation Reduction Act, expanding eligibility to include Part B drugs for the first time and proposing a single maximum fair price across Part B and Part D. While focused on Medicare policy, these negotiated prices have downstream implications for Medicaid managed care organizations through potential impacts on best price calculations and supplemental rebate agreements. The guidance also refines manufacturer exclusion criteria and seeks comment on how to evaluate therapeutic alternatives.

advisory.avalerehealth.com →
Avalere · Jun 6

Literature Review Examines PBM Functions and Value Across Payer Types, Including Managed Medicaid

Avalere's white paper synthesizes published evidence on PBM roles across the healthcare system, including their administration of prescription benefits for managed Medicaid plans alongside commercial, employer, and Medicare Part D populations. The review examines PBM impact on costs, access, and clinical outcomes, finding evidence of adherence improvements and cost savings through rebate negotiations, while acknowledging heightened regulatory scrutiny from federal and state policymakers. For Medicaid MCO pharmacy directors and compliance teams, the paper provides context on PBM value propositions and evolving oversight landscape relevant to their vendor relationships and state contract requirements.

advisory.avalerehealth.com →
Avalere · May 19

Opioid Use Disorder Costs $163K Per Case Annually to Payers and Government; Medication-Assisted Treatment Shows Net Savings

Avalere's national and state-level modeling quantifies the economic burden of opioid use disorder at nearly $1 trillion annually, with state and local government costs ranging from $137 to $524 per capita depending on geography. The analysis demonstrates that medication-assisted treatments—including methadone, buprenorphine formulations, and behavioral therapy—generate significant per-case cost savings, a finding directly relevant to Medicaid MCO benefit design, utilization management policies, and state pharmacy carve-in/carve-out decisions. With Medicaid covering a disproportionate share of individuals with substance use disorders, these cost-offset calculations inform managed care contracting, quality incentives, and state budget planning.

advisory.avalerehealth.com →
Avalere · May 14

GLP-1 Market Analysis Includes Managed Medicaid Claims Data on Utilization Patterns

Avalere analyzed pharmacy claims across payer types including Managed Medicaid to assess on-label and off-label use of GLP-1 and GIP/GLP-1 receptor agonists for diabetes and weight management. The piece examines product differentiation strategies for manufacturers and notes that USP Drug Classification limitations affect coverage decisions in non-Part D plans. While focused primarily on manufacturer strategy and market dynamics, the analysis incorporates Medicaid managed care data and touches on formulary implications relevant to MCO pharmacy benefit management.

advisory.avalerehealth.com →
Avalere · May 8

Trump Administration's First 100 Days: What It Means for Medicaid Spending and State Flexibilities

This Avalere webinar recap addresses multiple early Trump administration healthcare policy shifts, including a dedicated discussion on federal and state government healthcare spending covering Medicaid and Medicare reform prospects under reconciliation, CMMI model prioritization, state Medicaid flexibilities, and state upper payment limits. For Medicaid managed care stakeholders, the segment on reconciliation outlook and state flexibilities signals potential near-term funding and regulatory shifts worth monitoring, though the bulk of the webinar addresses non-Medicaid topics like drug pricing and public health.

avalerehealth.com →
Avalere · May 1

Proposed Medicaid Funding Reforms Could Cut Federal Children's Healthcare Spending by Up to $114 Billion Over Decade

Avalere modeling of three Congressional funding reform scenarios—per capita caps, expansion FMAP reductions, and removal of the 50% FMAP floor—projects total federal Medicaid cuts of $436-779 billion over ten years, with children's services losing between $57-114 billion. The analysis breaks down state-by-state impacts across different reform approaches, showing per capita caps would affect all states uniformly while FMAP changes would create highly variable impacts depending on expansion status. These projections provide MCOs and state Medicaid directors critical baseline data for understanding how federal funding restructuring could affect managed care capitation rates and children's service adequacy.

advisory.avalerehealth.com →
Avalere · Apr 22

Federal Push to Mandate Medicaid Work Requirements Could Force MCO Eligibility and Enrollment Changes

With Congress seeking Medicaid savings through budget reconciliation, mandatory work requirements across states are gaining momentum as a cost-cutting measure. The analysis reviews how past state implementations in Arkansas and Georgia led to coverage loss and administrative complexity, with key design variables including which populations face requirements, exemption processes, and reporting burdens. For MCOs, renewed work requirements would require significant changes to eligibility verification systems, member outreach, and retention strategies while potentially shrinking enrollment.

advisory.avalerehealth.com →
Avalere · Apr 21

Executive Order Directs HHS to Strengthen Medicaid Drug Rebate Accuracy and State Cost Management Tools

A new executive order from President Trump instructs federal agencies to develop recommendations within 180 days for improving Medicaid drug rebate accuracy, advancing value-based payment arrangements for pharmaceuticals, and supporting state-level strategies to manage drug spending. While much of the order focuses on Medicare reforms—including changes to IRA negotiation guidance and new CMMI pricing models—the Medicaid provisions signal potential federal action that could reshape how MCOs and states approach pharmacy benefit design and financial management. The directive suggests increased federal attention to pharmacy cost containment as a priority area for Medicaid managed care plans.

advisory.avalerehealth.com →
Avalere · Apr 21

PBM Delinking Legislation Could Reshape Medicaid MCO Pharmacy Contracting Models

Federal proposals to prohibit PBMs from earning compensation tied to drug prices or manufacturer rebates—requiring instead flat service fees—could fundamentally change how Medicaid managed care plans contract for pharmacy benefit management. While delinking bills have focused primarily on Medicare Part D and commercial markets, the policy shift would affect PBM operations across all lines of business including Medicaid, potentially altering incentive structures that currently encourage deeper manufacturer discounts. MCOs would need to evaluate how mandatory flat-fee arrangements impact their ability to maximize drug rebates and manage pharmacy costs under capitated payment models.

advisory.avalerehealth.com →
Avalere · Apr 1

ACA Marketplace Tax Credit Expiration Could Shift Coverage Options for Medicaid Redetermination Population

Avalere projects that 18 million Americans receiving enhanced ACA marketplace premium tax credits will lose subsidies if they expire in 2025, including nearly 5 million adults ages 50–64. The analysis notes that marketplace enrollment surged partly due to Medicaid redeterminations following the end of the COVID-19 continuous coverage requirement, with approximately 4 million people ages 50–64 disenrolled from Medicaid between 2023 and 2024. The expiration could affect coverage pathways for populations that transitioned from Medicaid to marketplace plans during unwinding.

advisory.avalerehealth.com →
Avalere · Mar 28

Health Plans Flag Patient Access and Cost Concerns as States Weigh Drug Price Caps

Avalere surveyed health plan executives on Prescription Drug Affordability Boards (PDABs) and upper payment limits (UPLs) now authorized in four states. Plans anticipate UPLs will force changes to formularies, cost-sharing, and pharmacy reimbursement, with 80% identifying patients as most impacted and most expecting increased out-of-pocket costs despite state affordability goals. While focused on commercial and state policy broadly, the findings have direct implications for Medicaid managed care plans operating in states with PDAB authority, particularly around pharmacy benefits and network adequacy.

advisory.avalerehealth.com →
Avalere · Mar 25

Federal Policy Shifts and Transplant Reforms May Reshape Kidney Care Coverage in 2025

The Trump administration's early termination of the ESRD Treatment Choices model and ongoing transplant system reforms under the Increasing Organ Transplant Access model will affect how kidney care is delivered and paid for in 2025. These federal policy changes carry implications for Medicaid managed care organizations covering members with chronic kidney disease and end-stage renal disease, though the piece focuses primarily on Medicare policy with only indirect Medicaid relevance.

advisory.avalerehealth.com →
Avalere · Feb 28

Behavioral Health Policy Shifts Present Coverage and Compliance Challenges for Payers

The piece examines how 2024's strengthened mental health parity enforcement and emerging psychedelic treatments are creating new compliance pressures and potential coverage expansion obligations for health plans. While it addresses behavioral health policy changes affecting payer compliance and benefit design, the analysis does not specifically focus on Medicaid managed care or distinguish Medicaid implications from commercial and employer-sponsored coverage. The relevance to Medicaid MCOs is real but indirect, as parity rules and treatment innovations affect all behavioral health payers.

advisory.avalerehealth.com →

Get the daily briefing.